Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)

~51 mi. (Floreşti, Romania, +158 more cities)

S.C. Radiotherapy Center Cluj S.R.L ( Site 2503)

Non-Small Cell Lung Carcinoma

olaparib, +4 more drugs

chemotherapy, +3 more types

Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)

~51 mi. (Floreşti, Romania, +105 more cities)

SC Radiotherapy Center Cluj SRL ( Site 1105)

ATM Loss, +62 more biomarkers

Breast Carcinoma, +2 more conditions

olaparib

targeted therapy

A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)

~58 mi. (Cluj-Napoca, Romania, +356 more cities)

Institutul Oncologic Prof. Dr. Ion Chiricuta

HER2 Positive

Invasive Breast Carcinoma

fam-trastuzumab deruxtecan

targeted therapy

Pembrolizumab (MK-3475) Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma (MK-3475-630/KEYNOTE-630)

~58 mi. (Cluj-Napoca, Romania, +137 more cities)

Spitalul Universitar CF Cluj-Napoca ( Site 1103), +1 more facility

Skin Squamous Cell Carcinoma

pembrolizumab

immunotherapy

Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)

~58 mi. (Cluj-Napoca, Romania, +126 more cities)

Institutul Oncologic Prof.Dr. Ion Chiricuta Cluj-Napoca ( Site 0392), +1 more facility

Adenocarcinoma of the Gastroesophageal Junction, +1 more condition

FOLFOX regimen, +3 more drugs

chemotherapy, +2 more types

Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)

~58 mi. (Cluj-Napoca, Romania, +92 more cities)

Institutul Oncologic Prof.Dr. Ion Chiricuta Cluj-Napoca ( Site 0249)

Bladder Urothelial Carcinoma

chemotherapy, +2 more drugs

chemotherapy, +2 more types

Study of Olaparib (MK-7339) in Combination With Pembrolizumab (MK-3475) in the Treatment of Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer (MK-7339-007/KEYLYNK-007)

~58 mi. (Cluj-Napoca, Romania, +115 more cities)

Medisprof ( Site 1102)

ATM Loss, +27 more biomarkers

Breast Carcinoma, +2 more conditions

olaparib, +1 more drug

immunotherapy, +1 more type

A Study of Brigatinib Compared to Alectinib in Adults With Non-Small-Cell Lung Cancer

~58 mi. (Cluj-Napoca, Romania, +87 more cities)

Institutul Oncologic Prof. Dr. Ion Chiricu

ALK Fusion

Non-Small Cell Lung Carcinoma

brigatinib

targeted therapy

A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)

~100 mi. (Gyula, Hungary, +144 more cities)

Bekes Megyei Kozponti Korhaz - Pandy Kalman Tagkorhaza ( Site 2309)

Clear Cell Renal Cell Carcinoma

belzutifan, +3 more drugs

immunotherapy, +1 more type

Efficacy and Safety of Olaparib (MK-7339) With or Without Bevacizumab Compared to Bevacizumab With a Fluoropyrimidine in Unresectable or Metastatic Colorectal Cancer (CRC) (MK-7339-003/LYNK-003)

~100 mi. (Gyula, Hungary, +105 more cities)

Bekes Megyei Kozponti Korhaz - Pandy Kalman Tagkorhaza ( Site 1432)

Colorectal Adenocarcinoma

bevacizumab, +1 more drug

targeted therapy